Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma

Francesco Merli, Massimo Federico, Paolo Avanzini, Fiorella Ilariucci, Caterina Stelitano, Emilio Iannitto, Mariangela Colombi, Daniele Vallisa, Giuseppe Santagati, Lino Piccinini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Objective. Aim of the study was to assess the efficacy of VEMB, a short-lasting therapeutic regimen (50 days) which alternates two myelotoxic drugs (cyclophosphamide and mitoxantrone) every week with two less hematologically toxic drugs (vincristine and bleomycin) in the treatment of aggressive NHL in the elderly (over 70). Design and Methods. Between November 1994 and March 1996, 37 patients aged more than 70 years, with highly or moderately malignant NHL (according to the Working Formulation) have been enrolled into the study. The stage of the disease ranged between II and IV according to Arm Arbor. Mean age was 77 years; 14 patients (38%) had stage IV; 19 patients (51%) had LDH higher than normal; 26 patients (70%) had extranodal and 9 patients (24%) had bulky disease at time of diagnosis. Results. Sixty-two percent of patients achieved a complete and 22% a partial remission. Non-responders amounted to 5%. Four patients (11%) died during the therapy. Nine patients (24%) experienced grade III-IV neutropenia. The most frequently observed event was mild neurotoxicity (43% of cases). The overall survival rate at 30 months was 55%. DFS at 24 months was 66%. Interpretation and Conclusions. VEMB is a therapeutic regimen whose efficacy is comparable to that of the other derived MACOP-B therapeutic regimens used in the elderly NHL. It has proved to have a good feasibility, though the number of toxic deaths should not be neglected.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalHaematologica
Volume83
Issue number3
Publication statusPublished - Mar 1998

Fingerprint

Mitoxantrone
Vincristine
Non-Hodgkin's Lymphoma
Cyclophosphamide
Poisons
Bleomycin
Therapeutics
indium-bleomycin
Neutropenia
Pharmaceutical Preparations
Survival Rate

Keywords

  • Chemotherapy
  • Dose intensity
  • Elderly
  • Non Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. / Merli, Francesco; Federico, Massimo; Avanzini, Paolo; Ilariucci, Fiorella; Stelitano, Caterina; Iannitto, Emilio; Colombi, Mariangela; Vallisa, Daniele; Santagati, Giuseppe; Piccinini, Lino.

In: Haematologica, Vol. 83, No. 3, 03.1998, p. 217-221.

Research output: Contribution to journalArticle

Merli, F, Federico, M, Avanzini, P, Ilariucci, F, Stelitano, C, Iannitto, E, Colombi, M, Vallisa, D, Santagati, G & Piccinini, L 1998, 'Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma', Haematologica, vol. 83, no. 3, pp. 217-221.
Merli, Francesco ; Federico, Massimo ; Avanzini, Paolo ; Ilariucci, Fiorella ; Stelitano, Caterina ; Iannitto, Emilio ; Colombi, Mariangela ; Vallisa, Daniele ; Santagati, Giuseppe ; Piccinini, Lino. / Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. In: Haematologica. 1998 ; Vol. 83, No. 3. pp. 217-221.
@article{a430a25bd4fb440bbef615b21d6033c6,
title = "Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma",
abstract = "Background and Objective. Aim of the study was to assess the efficacy of VEMB, a short-lasting therapeutic regimen (50 days) which alternates two myelotoxic drugs (cyclophosphamide and mitoxantrone) every week with two less hematologically toxic drugs (vincristine and bleomycin) in the treatment of aggressive NHL in the elderly (over 70). Design and Methods. Between November 1994 and March 1996, 37 patients aged more than 70 years, with highly or moderately malignant NHL (according to the Working Formulation) have been enrolled into the study. The stage of the disease ranged between II and IV according to Arm Arbor. Mean age was 77 years; 14 patients (38{\%}) had stage IV; 19 patients (51{\%}) had LDH higher than normal; 26 patients (70{\%}) had extranodal and 9 patients (24{\%}) had bulky disease at time of diagnosis. Results. Sixty-two percent of patients achieved a complete and 22{\%} a partial remission. Non-responders amounted to 5{\%}. Four patients (11{\%}) died during the therapy. Nine patients (24{\%}) experienced grade III-IV neutropenia. The most frequently observed event was mild neurotoxicity (43{\%} of cases). The overall survival rate at 30 months was 55{\%}. DFS at 24 months was 66{\%}. Interpretation and Conclusions. VEMB is a therapeutic regimen whose efficacy is comparable to that of the other derived MACOP-B therapeutic regimens used in the elderly NHL. It has proved to have a good feasibility, though the number of toxic deaths should not be neglected.",
keywords = "Chemotherapy, Dose intensity, Elderly, Non Hodgkin's lymphoma",
author = "Francesco Merli and Massimo Federico and Paolo Avanzini and Fiorella Ilariucci and Caterina Stelitano and Emilio Iannitto and Mariangela Colombi and Daniele Vallisa and Giuseppe Santagati and Lino Piccinini",
year = "1998",
month = "3",
language = "English",
volume = "83",
pages = "217--221",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma

AU - Merli, Francesco

AU - Federico, Massimo

AU - Avanzini, Paolo

AU - Ilariucci, Fiorella

AU - Stelitano, Caterina

AU - Iannitto, Emilio

AU - Colombi, Mariangela

AU - Vallisa, Daniele

AU - Santagati, Giuseppe

AU - Piccinini, Lino

PY - 1998/3

Y1 - 1998/3

N2 - Background and Objective. Aim of the study was to assess the efficacy of VEMB, a short-lasting therapeutic regimen (50 days) which alternates two myelotoxic drugs (cyclophosphamide and mitoxantrone) every week with two less hematologically toxic drugs (vincristine and bleomycin) in the treatment of aggressive NHL in the elderly (over 70). Design and Methods. Between November 1994 and March 1996, 37 patients aged more than 70 years, with highly or moderately malignant NHL (according to the Working Formulation) have been enrolled into the study. The stage of the disease ranged between II and IV according to Arm Arbor. Mean age was 77 years; 14 patients (38%) had stage IV; 19 patients (51%) had LDH higher than normal; 26 patients (70%) had extranodal and 9 patients (24%) had bulky disease at time of diagnosis. Results. Sixty-two percent of patients achieved a complete and 22% a partial remission. Non-responders amounted to 5%. Four patients (11%) died during the therapy. Nine patients (24%) experienced grade III-IV neutropenia. The most frequently observed event was mild neurotoxicity (43% of cases). The overall survival rate at 30 months was 55%. DFS at 24 months was 66%. Interpretation and Conclusions. VEMB is a therapeutic regimen whose efficacy is comparable to that of the other derived MACOP-B therapeutic regimens used in the elderly NHL. It has proved to have a good feasibility, though the number of toxic deaths should not be neglected.

AB - Background and Objective. Aim of the study was to assess the efficacy of VEMB, a short-lasting therapeutic regimen (50 days) which alternates two myelotoxic drugs (cyclophosphamide and mitoxantrone) every week with two less hematologically toxic drugs (vincristine and bleomycin) in the treatment of aggressive NHL in the elderly (over 70). Design and Methods. Between November 1994 and March 1996, 37 patients aged more than 70 years, with highly or moderately malignant NHL (according to the Working Formulation) have been enrolled into the study. The stage of the disease ranged between II and IV according to Arm Arbor. Mean age was 77 years; 14 patients (38%) had stage IV; 19 patients (51%) had LDH higher than normal; 26 patients (70%) had extranodal and 9 patients (24%) had bulky disease at time of diagnosis. Results. Sixty-two percent of patients achieved a complete and 22% a partial remission. Non-responders amounted to 5%. Four patients (11%) died during the therapy. Nine patients (24%) experienced grade III-IV neutropenia. The most frequently observed event was mild neurotoxicity (43% of cases). The overall survival rate at 30 months was 55%. DFS at 24 months was 66%. Interpretation and Conclusions. VEMB is a therapeutic regimen whose efficacy is comparable to that of the other derived MACOP-B therapeutic regimens used in the elderly NHL. It has proved to have a good feasibility, though the number of toxic deaths should not be neglected.

KW - Chemotherapy

KW - Dose intensity

KW - Elderly

KW - Non Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0031970590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031970590&partnerID=8YFLogxK

M3 - Article

C2 - 9573675

AN - SCOPUS:0031970590

VL - 83

SP - 217

EP - 221

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -